Filing Flows › Embecta (EMBC) › Q2 FY26 › vs Q2 FY25
Embecta (EMBC) Q2 FY26 vs Q2 FY25 (year over year)
Embecta's revenue fell $37.2M (-14%) from $259M in Q2 FY25 to $222M in Q2 FY26. The biggest changes: Pen Needles −$33.6M (-18%); Syringes −$2.5M (-9%); Contract Manufacturing −$1.9M (-43%).
Embecta, Q2 FY26: revenue $222M (-14% year over year), operating margin 15.8%, net loss $4.1M, operating cash flow $31.1M. The chart draws each line against Q2 FY25, the increases inside each band.
Margins
| Q2 FY26 | Q2 FY25 | Change | |
|---|---|---|---|
| Free cash flow margin | 13.8% | 12.2% | +1.6 pts |
Every line
| Line | Q2 FY26 | Q2 FY25 | Change | % |
|---|---|---|---|---|
| Pen Needles | $155M | $188M | −$33.6M | -18% |
| Safety | $34.3M | $34.2M | $100K | +0.3% |
| Syringes | $26.3M | $28.8M | −$2.5M | -9% |
| Other | $4.0M | $3.3M | $700K | +21% |
| Contract Manufacturing | $2.5M | $4.4M | −$1.9M | -43% |
| Revenue | $222M | $259M | −$37.2M | -14% |
| Net loss | $4.1M | −$23.5M | $27.6M | — |
| Costs & expenses | $226M | $259M | −$33.1M | -13% |
| Operating costs | $187M | $196M | −$9.3M | -5% |
| Interest & other, net | $25.5M | $27.1M | −$1.6M | -6% |
| Income tax | $13.6M | $12.3M | $1.3M | +11% |
| Cost of revenue | $94.0M | $94.9M | −$900K | -0.9% |
| Research & development | $5.4M | $8.0M | −$2.6M | -32% |
| SG&A | $76.2M | $79.6M | −$3.4M | -4% |
| Other operating costs | $11.2M | $13.6M | −$2.4M | -18% |
| Operating cash sources | $35.2M | $8.3M | $26.9M | +324% |
| Depreciation & amortization | $10.2M | $9.0M | $1.2M | +13% |
| Share-based compensation | $5.7M | $7.3M | −$1.6M | -22% |
| Working capital & other | $19.3M | −$8.0M | $27.3M | — |
| Net loss absorbed | $4.1M | −$23.5M | $27.6M | — |
| Operating cash flow | $31.1M | $31.8M | −$700K | -2% |
| Free Cash Flow (company-reported) | $30.6M | $31.7M | −$1.1M | -3% |
| Capital expenditures | $500K | $100K | $400K | +400% |
Questions
How much did Embecta's revenue grow year over year in Q2 FY26?
Embecta's revenue fell $37.2M (-14%) from $259M in Q2 FY25 to $222M in Q2 FY26.
What drove Embecta's revenue change in Q2 FY26?
Pen Needles −$33.6M (-18%); Syringes −$2.5M (-9%); Contract Manufacturing −$1.9M (-43%).